Levin Capital Strategies L.P. Has $522,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• Levin Capital Strategies L.P. reduced its Pfizer stock holdings by 53%, leaving it with 20,616 shares valued at approximately $522,000.
• Multiple institutional investors, including Clarity Asset Management Inc. and North Capital Inc., have recently acquired stakes in Pfizer, indicating ongoing interest in the company.
• Analysts have revised their price targets for Pfizer downward, with TD Cowen setting a new target at $28.00, while the overall ratings range from 'sell' to 'strong buy'.

Levin Capital Strategies L.P. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 53.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 20,616 shares of the biopharmaceutical company's stock after selling 23,217 shares during the period. Levin Capital Strategies L.P.'s holdings in Pfizer were worth $522,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of PFE. Clarity Asset Management Inc. acquired a new stake in Pfizer during the 4th quarter worth $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. TD Cowen lowered their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Trading Up 0.3%

PFE opened at $23.56 on Tuesday. The stock has a market capitalization of $133.95 billion, a P/E ratio of 17.07, a P/E/G ratio of 0.85 and a beta of 0.52. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm's fifty day simple moving average is $24.37 and its 200 day simple moving average is $24.53. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.